Diabetic Macular Edema: Inflammatory Markers and Their Role as Potential Therapeutic Targets

Author(s)/Faculty: Peter K. Kaiser, MD; Michael S. Ip, MD; Judy E. Kim, MD
Release Date: 3/8/2022Expiration Date: 3/7/2023
Credit Type: CME / CME with ABO Continuing Certification Number of Credits: 0.75
Content Type: LectureProvider:
Diabetic macular edema (DME) is a leading cause of visual impairment. While treatment advances have improved the overall visual outcomes for most patients with DME, there continue to be unmet needs in the care of these individuals. The response to anti-vascular endothelial growth factor therapies can be variable, and multicenter trials that used a high number of injections, which resulted in the best functional and anatomic outcomes, are difficult to replicate in real-world practice. The potential of corticosteroid implants to improve visual outcomes in DME has been demonstrated. In this educational activity, expert clinicians discuss the role of cytokines in the pathogenesis of DME and the latest data on intravitreal corticosteroid therapy.